![Patient and public perspectives on cell and gene therapies: a systematic review | Nature Communications Patient and public perspectives on cell and gene therapies: a systematic review | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-020-20096-1/MediaObjects/41467_2020_20096_Fig1_HTML.png)
Patient and public perspectives on cell and gene therapies: a systematic review | Nature Communications
![Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues - ScienceDirect Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497121013239-grabsf1.jpg)
Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues - ScienceDirect
Gene & Cell Therapy FAQs | ASGCT - American Society of Gene & Cell Therapy | ASGCT - American Society of Gene & Cell Therapy
![Comparison between germline and somatic gene editing/therapy in terms... | Download Scientific Diagram Comparison between germline and somatic gene editing/therapy in terms... | Download Scientific Diagram](https://www.researchgate.net/publication/357825083/figure/fig1/AS:1181914622898178@1658801813778/Comparison-between-germline-and-somatic-gene-editing-therapy-in-terms-of-the-types-of.png)
Comparison between germline and somatic gene editing/therapy in terms... | Download Scientific Diagram
![Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access - The Lancet Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access - The Lancet](https://www.thelancet.com/cms/attachment/5789602b-8611-4d1f-a049-ef7f9f723757/gr1_lrg.jpg)